Neuronetics outlines >9% 2026 revenue growth target while piloting new TMS models and preparing for Compass therapy launch
Source: SeekingAlpha
2026-03-17 13:13:09 ET
More on Neuronetics
- Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
- Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
- Neuronetics expects Q4 revenue of $41.8 million
- Seeking Alpha’s Quant Rating on Neuronetics
- Historical earnings data for Neuronetics
Read the full article on Seeking Alpha
For further details see:
Neuronetics outlines >9% 2026 revenue growth target while piloting new TMS models and preparing for Compass therapy launch
Neuronetics Inc.
NASDAQ: STIM
STIM Trading
-4.95% G/L:
$1.3925 Last:
407,972 Volume:
$1.48 Open:
STIM Latest News
March 17, 2026 07:50:00 am
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 17, 2026 07:45:00 am
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
STIM Stock Data
$103,071,313
37,324,827
5.78%
18
N/A
Medical Diagnostics & Screening
Healthcare
US
Malvern
